Effecting Immune Reset through Deep B-Cell Depletion with CLN-978: Early Clinical & Translational Insights
- Summarising emerging clinical data evaluating the safety, tolerability, and preliminary clinical activity of the CD19 x CD3 TCE CLN-978 across autoimmune patient populations
- Characterising the depth, durability, and tissue-level impact of B-cell depletion achieved through enhanced target engagement and extended half-life design
- Describing how emerging clinical and biomarker observations for CLN-978 can be utilised to rapidly advance the development of T cell engagers in autoimmune disease indications